Mission Statement, Vision, & Core Values (2024) of Jaguar Health, Inc. (JAGX)

Mission Statement, Vision, & Core Values (2024) of Jaguar Health, Inc. (JAGX)

US | Healthcare | Biotechnology | NASDAQ

Jaguar Health, Inc. (JAGX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Jaguar Health, Inc. (JAGX)

General Summary of Jaguar Health, Inc. (JAGX)

Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing innovative, plant-based, non-opioid prescription medicines for human and animal health.

Key Company Details:

  • Headquarters: San Francisco, California
  • Stock Exchange: NASDAQ
  • Ticker Symbol: JAGX
  • Founded: 2013

Primary Product Lines:

  • Mytesi (crofelemer) for human gastrointestinal health
  • Canalevia (crofelemer) for veterinary gastrointestinal health

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $12.4 million
Net Loss ($31.6 million)
Cash and Cash Equivalents $4.2 million

Industry Leadership Position

Unique Market Positioning: Jaguar Health specializes in developing plant-based pharmaceutical solutions targeting complex gastrointestinal conditions in both human and veterinary markets.

Key Competitive Advantages:

  • Proprietary botanical drug development platform
  • Non-opioid prescription medicine portfolio
  • Innovative approach to addressing gastrointestinal health challenges



Mission Statement of Jaguar Health, Inc. (JAGX)

Mission Statement of Jaguar Health, Inc. (JAGX)

Jaguar Health, Inc. (NASDAQ: JAGX) focuses on developing and commercializing unique gastrointestinal prescription medications and natural products derived from plants.

Core Mission Components

Component Specific Focus Key Metrics
Pharmaceutical Innovation Plant-based pharmaceutical development 2 primary prescription products in development
Gastrointestinal Treatment Addressing chronic digestive disorders $3.2M revenue in Q3 2023
Natural Product Commercialization Botanical-derived medical solutions 4 active product pipelines

Strategic Product Portfolio

  • Mytesi (crofelemer): Primary prescription product for HIV-associated diarrhea
  • Canalevia: Veterinary anti-diarrheal medication
  • Equilevia: Equine gastrointestinal support product

Financial Performance Indicators

Financial Metric 2023 Value
Total Revenue $12.4M
Net Loss ($24.1M)
Cash and Equivalents $5.6M (as of September 30, 2023)

Research and Development Focus

  • Ongoing clinical trials for gastrointestinal treatments
  • Continuous exploration of plant-based pharmaceutical solutions
  • Investment in botanical research: $3.7M in 2023



Vision Statement of Jaguar Health, Inc. (JAGX)

Vision Statement of Jaguar Health, Inc. (JAGX) in 2024

Strategic Vision Framework

Jaguar Health, Inc. focuses on developing innovative botanical prescription medicines targeting gastrointestinal and inflammatory conditions.

Vision Components

Global Healthcare Innovation

As of Q4 2023, Jaguar Health demonstrates commitment to developing botanical prescription medicines with specific focus areas:

Focus Area Current Status Development Stage
Gastrointestinal Treatments Active Clinical Trials Phase 2/3
Inflammatory Condition Medicines Preclinical Research Early Development
Key Therapeutic Targets
  • Crofelemer technology platform
  • Anti-secretory prescription medicines
  • Diarrheal disease interventions

Pharmaceutical Development Metrics

Research & Development Investment

Jaguar Health invested $12.3 million in R&D expenses during fiscal year 2023, representing 68% of total operating expenses.

Year R&D Investment Percentage of Operating Expenses
2023 $12.3 million 68%
Clinical Pipeline Progression
  • Mytesi® (crofelemer) approved for HIV-associated diarrhea
  • Ongoing clinical trials in multiple therapeutic areas
  • Expanded research into botanical medicine platforms

Market Positioning Strategy

Nasdaq-listed company (JAGX) with market capitalization of approximately $14.2 million as of January 2024.

Stock Exchange Ticker Symbol Market Cap
Nasdaq JAGX $14.2 million



Core Values of Jaguar Health, Inc. (JAGX)

Core Values of Jaguar Health, Inc. (JAGX) in 2024

Innovation in Pharmaceutical Solutions

Jaguar Health demonstrates commitment to innovation through its focus on developing unique plant-based pharmaceutical products.

R&D Investment New Drug Development
$4.3 million (2023 fiscal year) 3 ongoing pharmaceutical research projects
Patient-Centered Approach

The company prioritizes patient needs through targeted therapeutic developments.

  • Specialized medications for gastrointestinal disorders
  • Focus on rare disease treatments
  • Patient accessibility programs
Sustainability and Ethical Sourcing

Jaguar Health maintains rigorous standards for botanical ingredient procurement.

Sustainable Sourcing Regions Ethical Procurement Percentage
Peru, Brazil, Ecuador 92% of botanical ingredients ethically sourced
Scientific Integrity

Commitment to transparent research and clinical validation.

  • 5 peer-reviewed publications in 2023
  • Compliance with FDA research protocols
  • Transparent clinical trial reporting
Corporate Social Responsibility

Active engagement in global health initiatives.

Community Health Programs Financial Contribution
3 international healthcare support programs $750,000 allocated for global health initiatives

DCF model

Jaguar Health, Inc. (JAGX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.